Sight Sciences, Inc. ((SGHT)) has held its Q3 earnings call. Read on for the main highlights of the call.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The recent earnings call for Sight Sciences, Inc. presented a mixed sentiment, combining positive strides with notable challenges. On the upside, the company increased its revenue guidance, achieved successful payer coverage for TearCare, and experienced growth in its Surgical Glaucoma revenue. However, these positive developments were tempered by a decline in overall revenue and Dry Eye segment revenue, the impact of tariff costs, and a reported net loss.
Increased Revenue Guidance
Sight Sciences raised its full-year 2025 revenue guidance to a range of $76 million to $78 million, up from the previous guidance of $72 million to $76 million. This upward revision reflects the company’s confidence in its strategic initiatives and market positioning.
Surgical Glaucoma Revenue Growth
The Surgical Glaucoma segment reported a revenue of $19.7 million in Q3 2025, marking a 6% increase compared to the same period in the previous year. This growth underscores the successful adoption of the company’s OMNI Surgical Glaucoma technology.
Successful Payer Coverage for TearCare
The company achieved significant milestones in payer coverage for TearCare, securing pricing schedules with First Coast Service Options and Novitas Solutions. This coverage encompasses 10.4 million Medicare lives and establishes a payment rate of approximately $1,142, enhancing market access for reimbursed interventional dry eye procedures.
Record High for Ordering Accounts
Ordering accounts reached a record high for the second consecutive quarter, with a 2% sequential increase and an 8% increase compared to the previous year. This indicates a growing demand and market penetration for Sight Sciences’ products.
Management Restructuring
Sight Sciences announced a management restructuring with the promotion of Ali Bauerlein to Chief Operating Officer and Jim Rodberg to Chief Financial Officer. Both individuals bring substantial experience within the company, which is expected to strengthen its leadership team.
Overall Revenue Decrease
Despite some positive developments, the company reported a total revenue of $19.9 million for Q3 2025, marking a 1% decrease compared to the same period in the prior year. This decline highlights ongoing challenges in certain segments.
Dry Eye Revenue Decline
The Dry Eye segment experienced a significant revenue drop from $1.5 million to $0.2 million. This decrease is attributed to fewer SmartLids sales as the company focused on achieving reimbursed market access for TearCare procedures.
Tariff Costs Impact
The Surgical Glaucoma gross margin was negatively impacted by tariff costs, with $0.4 million in costs associated with tariffs in Q3 2025. This factor contributed to the financial challenges faced by the company.
Net Loss Reported
Sight Sciences reported a net loss of $8.2 million or $0.16 per share for Q3 2025, compared to a net loss of $11.1 million or $0.22 per share in the prior year. While the loss decreased year-over-year, it remains a critical area for improvement.
Forward-Looking Guidance
In its forward-looking guidance, Sight Sciences highlighted strong performance and strategic advancements for fiscal year 2025. The company raised its full-year revenue guidance, driven by the adoption of its OMNI Surgical Glaucoma technology. Additionally, it lowered its adjusted operating expense guidance, aiming for a reduction of 9% to 11% compared to 2024. The strategic importance of recent Medicare pricing schedules for TearCare was emphasized, expected to expand market opportunities. These developments, along with momentum in the Surgical Glaucoma segment, are anticipated to drive sustained long-term growth.
In summary, Sight Sciences’ earnings call presented a balanced view of its current performance and future prospects. While the company faces challenges such as revenue declines and tariff impacts, it also demonstrates resilience through increased revenue guidance and strategic advancements. The focus on expanding market access and improving operational efficiency positions Sight Sciences for potential growth in the coming years.